July 2019
-
Media ReleaseSandoz announces first patient enrolled in clinical study for proposed biosimilar denosumab in osteoporosisIntegrated Phase I/lll study for proposed biosimilar denosumab to confirm matching efficacy, safety and immunogenicity with reference medicine1 Osteoporosis accounts for 8.9m bone fractures…
-
Media ReleaseNovartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increasedContinuing operations1 net sales up 8% (cc2, +4% USD) driven by: Cosentyx at USD 858 million, +25% (cc) mainly driven by continued strong US growth (+31%) Entresto grew to USD 421 million, +81% (…
-
Media ReleaseSandoz extends SYMJEPI™ (epinephrine) Injection launch to US pharmacies to help improve patient access to life-saving medicineAdult and pediatric doses immediately available as single-dose, pre-filled syringe and device combination for emergency treatment of Type 1 allergic reactions, including anaphylaxis1 SYMJEPI will…
-
Media ReleaseSandoz launches oncology generic gefitinib in 13 EU countries at loss of market exclusivity, expanding access to essential medicineSandoz gefitinib indicated for adult patients with locally advanced or metastatic non-small cell lung cancer1 with activating mutations of EGFR-TK1 More than 300,000 European men and women are…
June 2019
-
Media ReleaseSandoz enters agreement with Kit Check to track, automate restocking of products in U.S. hospitalsSandoz and Kit Check will help hospital pharmacies cut costs, reduce risk, and better support hospital staff in treating their patients safely and more efficiently Collaboration will optimize…
-
Media ReleaseNew Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacyData show switching to Hyrimoz® (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis1…
May 2019
-
Media ReleaseSandoz announces plan to improve competitiveness and realign the organization, to drive ongoing Transformation and support future growthTwo-stage strategic Transformation plan foresees measures for organizational realignment, followed by increased investments to drive growth segments Realignment of organization involves a planned…
-
Media ReleaseSandoz demonstrates strategic focus on China, with first-of-a-kind generic approval under Quality Consistency Evaluation systemSandoz receives generic approval for Rosuvastatin from China's National Medical Products Administration (NMPA) under Quality Consistency Evaluation (QCE) system Generic approval under China's…